Rob

Systematic video-analysis of motor events during REM sleep in idiopathic REM sleep behavior disorder, follow-up and DAT-SPECT

Biomarkers, iRBD /

Patients with higher amounts of violent Motor Events had a greater risk of phenoconversion; therefore, their role as a predictor should be considered. Additionally, ME were associated with nigrostriatal degeneration, according to DAT-SPECT. These findings indicate that the degree of the clinical severity of motor manifestations in iRBD reflects the severity of the disease. CLICK […]

Systematic video-analysis of motor events during REM sleep in idiopathic REM sleep behavior disorder, follow-up and DAT-SPECT Read More »

Gut Microbiome Changes with Osteopathic Treatment of Constipation in Parkinson’s Disease: A Pilot Study

Biomarkers, Constipation, Gut Microbiota /

The gut microbiome shifted among individuals with constipation and PD after four weekly treatments with the OMM-sequence. Changes in the gut microbiome Post-OMM were associated with UPDRS results and constipation measures. Clinical trials and studies to develop the gut microbiome into a validated biomarker for PD are necessary to understand the impact of OMM in

Gut Microbiome Changes with Osteopathic Treatment of Constipation in Parkinson’s Disease: A Pilot Study Read More »

Potential roles of gut microbiota and microbial metabolites in Parkinson’s disease

Butyrate, Gut Dysbiosis, Gut Microbiota, Gut-Brain axis /

Parkinson’s disease (PD) is a complicated neurodegenerative disease attributed to multifactorial changes. However, its pathological mechanism remains undetermined. Accumulating evidence has revealed the emerging functions of gut microbiota and microbial metabolites, which can affect both the enteric nervous system and the central nervous system via the microbiota-gut-brain axis. Accordingly, intestinal dysbiosis might be closely associated

Potential roles of gut microbiota and microbial metabolites in Parkinson’s disease Read More »

Neuroprotective effects of short-chain fatty acids in MPTP induced mice model of Parkinson’s disease

Butyrate, Short Chain Fatty Acids /

Finally, the pros and cons of the current treatments for PD, including those targeting microbiota, are assessed. Advancements in research techniques, further studies on levels of specific strains and longitudinal prospective clinical trials are urgently needed for the identification of early diagnostic markers and the development of novel therapeutic approaches for PD. CLICK TO REVIEW

Neuroprotective effects of short-chain fatty acids in MPTP induced mice model of Parkinson’s disease Read More »

Air pollution, surrounding green, road proximity and Parkinson’s disease: A prospective cohort study

Parkinson's Disease /

We found that PM2.5 were associated with increased risk of incident PD while surrounding green was associated with decreased risk of PD. Future studies about PD etiology may benefit from including multiple environmental exposures to address potential joint associations. CLICK TO REVIEW

Air pollution, surrounding green, road proximity and Parkinson’s disease: A prospective cohort study Read More »

What We Fund: $19 Million to Advance New Therapies and Study Environmental Risks

Uncategorized /

The Michael J. Fox Foundation (MJFF) devotes our donor-raised dollars to the most promising scientific efforts to bring new treatments and cures closer to patient hands. In February and March, MJFF funded 56 new grants totaling nearly $19 million. https://www.michaeljfox.org/news/what-we-fund-19-million-advance-new-therapies-and-study-environmental-risks?em_cid=mc-a1b1R00000A5RyQ&et_cid=1855890&et_rid=574902244&et_lid=http%3a%2f%2fwww.michaeljfox.org%2fnews%2fwhat-we-fund-19-million-advance-new-therapies-and-study-environmental-risks%3fem_cid%3dmc-a1b1R00000A5RyQ

What We Fund: $19 Million to Advance New Therapies and Study Environmental Risks Read More »

Parkinson’s is announced long before the diagnosis

Constipation, iRBD, Olfactory, Sleep /

Parkinson’s disease is a progressive disease of the brain caused by the death of special nerve cells. The disease is characterized by movement disorders such as slowing movements, stiffness of the muscles, tremors or specific changes in the gait pattern. Often there can be many years before these typical symptoms permit a diagnosis of Parkinson’s disease. These can

Parkinson’s is announced long before the diagnosis Read More »

Gut Microbial Metabolites in Parkinson’s Disease: Implications of Mitochondrial Dysfunction in the Pathogenesis and Treatment

Gut Dysbiosis, Gut Microbiota, Metabolites, Mitochondria /

The search for therapeutic targets for Parkinson’s disease (PD) is hindered by the incomplete understanding of the pathophysiology of the disease. Mitochondrial dysfunction is an area with high potential. The neurobiological signaling connections between the gut microbiome and the central nervous system are incompletely understood. Multiple lines of evidence suggest that the gut microbiota participates

Gut Microbial Metabolites in Parkinson’s Disease: Implications of Mitochondrial Dysfunction in the Pathogenesis and Treatment Read More »